Table 1 Baseline and clinical characteristics of asthma and COPD cohorts (2008 data)
From: Using an electronic medical record (EMR) to conduct clinical trials: Salford Lung Study feasibility
| Â | Asthma only cohort | COPD cohort | COPD and asthma cohort 1 |
|---|---|---|---|
(N = 7981) | (N = 4478) | (N = 1718) | |
Age at diagnosis (years), mean (SD) | 33.1 (20.0) | 61.1 (12.9) | 59.2 (13.6) |
Male sex, n (%) | 3209 (40) | 2026 (45) | 672 (39) |
Smoking history, n (%) | Â | Â | Â |
Current | 2148 (27) | 1796 (40) | 639 (37) |
Former | 2579 (32) | 2326 (52) | 855 (50) |
Never | 3241 (41) | 356 (8) | 224 (13) |
Body Mass Index, n (%) | Â | Â | Â |
<18 | 88 (1) | 160 (4) | 41 (2) |
18-25 | 2370 (30) | 1686 (38) | 601 (35) |
26-30 | 1772 (22) | 1064 (24) | 407 (24) |
>30 | 2310 (29) | 1161 (26) | 510 (30) |
unknown | 1441 (18) | 407 (9) | 159 (9) |
FEV1 (L), mean (SD) | 2.42 (0.83) | 1.45 (0.60) | 1.48 (0.63) |
FEV1% predicted, mean (SD) | 86.0 (18.4) | 61.0 (19.7) | 62.7 (20.0) |
GOLD Stage, n (%) | Â | Â | Â |
  I | n/a | 583 (13) | 247 (14) |
  II | n/a | 2036 (45) | 713 (42) |
  III | n/a | 874 (20) | 307 (18) |
  IV | n/a | 200 (4) | 57 (3) |
  unknown | n/a | 785 (18) | 394 (23) |
Peak expiratory flow, mean (SD) | 393.7 (123.8) | n/a | n/a |
Medication, n (%) | Â | Â | Â |
SABA | 7492 (94) | 4189 (94) | 1638 (95) |
LABA | 777 (10) | 522 (12) | 252 (15) |
LAMA | 49 (<1) | 1617 (36) | 515 (30) |
LTRA | 359 (4) | 119 (3) | 91 (5) |
ICS monotherapy | 3364 (42) | 652 (15) | 332 (19) |
ICS plus LABA2 | 3190 (40) | 2484 (55) | 1128 (66) |
ICS plus LTRA or LAMA | 52 (<1) | 153 (3) | 53 (3) |
Cardiovascular comorbidities, | Â | Â | Â |
n(%)3 | Â | Â | Â |
Any | 2176 (27) | 2586 (58) | 964 (56) |
Acute MI | 226 (3) | 492 (11) | 150 (9) |
Hypertension | 2016 (25) | 2224 (50) | 852 (50) |
Stroke | 89 (1) | 226 (5) | 68 (4) |
Heart failure | 136 (2) | 467 (10) | 166 (10) |